MANAGEMENT OF STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i8.1806Keywords:
Broncodhilator, Chronic obstructive pulmonary disease, CorticosteroidsAbstract
Introduction: The goal of drug treatment for chronic obstructive pulmonary disease (COPD) is to relieve symptoms and lower the chance of future problems like flare-ups, disease progression, and death. Because COPD is not all the same, people respond differently to drug treatments. The best way to treat COPD now is with precision medicine, which uses clinical and biomarker data to make treatment decisions that are best for each person.
The aim: This article discusses management of stable chronic obstructive pulmonary disease.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search brought up 68 articles, whereas the results of our search on SagePub brought up 32 articles. The results of the search conducted for the last year of 2013 yielded a total 31 articles for PubMed and 15 articles for SagePub. In the end, we compiled a total of 14 papers, 10 of which came from PubMed and four of which came from SagePub. We included four research that met the criteria.
Conclusion: COPD treatment has evolved to match clinical characteristics and biomarkers to each patient. Hospitalizations and death have improved in triple combination treatment studies. However, COPD treatments are lacking, such as emphysema-slowing drugs. Despite progress, much remains.
References
Lumb AB. Nunn’s Applied Respiratory Physiology. 8th ed. Philadelphia: Elsevier; 2017.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD. 2017.
Kementerian Kesehatan Republik Indonesia. Riset Kesehatan Dasar [Internet] Jakarta; 2018. Available from:
http://www.depkes.go.id/resources/download/infoterkini/materi_rakorpop_
/Hasil Riskesdas 2018.pdf
Broaddus VC; Mason RJ; Ernst JD; et al. Murray & Nadel’s Textbook of Respiratory Medicine. Philadelphia: Elsevier Saunders; 2016.
Price SA LM. Patofisiologi Konsep Klinis Proses-Proses Penyakit. Jakarta: EGC; 2016.
World Health Organization’s. Chronic obstructive pulmonary disease (COPD). Geneva; 2017.
Adeloye D; Chua S; Lee C; et al. Global and Regional Estimates of COPD Prevalance: Systematic Review and Metaanalysis. J Glob Health. 2015;5(2):17–23.
Currie GP. ABC of COPD. London: Blackwell Publishing; 2011.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020 Jul;383(1):35–48.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018 May;378(18):1671–80.
Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu C-Q, Lipson DA. Single-inhaler fluticasone
furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respir Res. 2018 Jan;19(1):19.
Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May;1(3):210–23.
Malerba M, Nardin M, Santini G, Mores N, Radaeli A, Montuschi P. Single-inhaler triple therapy utilizing the oncedaily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. Ther Adv Respir Dis. 2018;12:1753466618760779.
Terry PD, Dhand R. Inhalation therapy for stable COPD: 20 years of GOLD reports. Adv Ther. 2020;37:1812–28.
Terry PD, Dhand R. Maintenance therapy with nebulizers in patients with stable COPD: need for reevaluation. Pulm Ther. 2020;6(2):177–92.
Lee HW, Park J, Jang EJ, Lee C-H. Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. Respir Res. 2020;21(1):1–15.
Chipps BE, Albers FC, Reilly L, Johnsson E, Cappelletti C, Papi A. Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study. BMJ open Respir Res. 2021 Dec;8(1).
Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Clin Ther. 2012 Aug;34(8):1655-66.e5.
Yoon J-K, Lee J-K, Lee C-H, Hwang Y Il, Kim H, Park D, et al. The association between eosinophil variability patterns and the efficacy of inhaled corticosteroids in stable COPD patients. Int J Chron Obstruct Pulmon Dis. 2020;2061–70.
Singh D. Pharmacological treatment of stable chronic obstructive pulmonary disease. Respirology. 2021;26(7):643– 51.
Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, et al. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled
Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. Adv Ther. 2020 Jun;37(6):2956–75.
Bruntol L, Dandan R, Knollmann B. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. Philadelphia: Mc Graw Hill Education; 2018.
Yang IA, Clarke MS, Sim EHA, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(7).
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
